99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile (Tc-Sestamibi), a new myocardial perfusion radiopharmaceutical, was injected intravenously in 11 patients within 4 hours of the onset of acute myocardial infarction before treatment with intravenous tissue-type plasminogen activator and 6-14 days later. Five patients with acute myocardial infarction who did not receive intravenous thrombolytic therapy underwent a similar injection of radiopharmaceutical. The absence of redistribution of Tc-Sestamibi permitted imaging with single-photon emission computed tomography up to 6 hours after intravenous injection to assess the distribution of myocardial perfusion at the time of administration. The region of hypoperfused myocardium on the initial images varied widely from 9% to 68% of the left ventricle and was significantly greater in anterior than in inferior infarcts (p<0.01). The region of hypoperfused myocardium on the final images varied widely from 0% to 63% of the left ventricle and was also greater in anterior infarcts (p<0.01). The final hypoperfused region correlated (r=-0.82) with the late resting ejection fraction and with the late regional wall motion score in the infarct segment for both anterior (r=-0.74) and inferior (r=-0.97) infarcts. There was a significant decrease (-13±11%, p <0.003) in the extent of hypoperfused myocardium between the initial and final studies in the patients who received thrombolytic therapy compared with an insignificant increase (4±6%, p >0.5) in the patients who did not receive thrombolytic therapy. Toinographic imaging with Tc-Sestamibi permits determination of the amount of hypoperfused myocardium "at risk" in acute myocardial infarction. The change in myocardial perfusion determined by Tc-Sestamibi before and after therapy in acute myocardial infarction is a promising tool for assessing treatment.
macroaggregated albumin and gated planar imaging, Feiring et al13 showed that the amount of myocardium "at risk" during acute myocardial infarction is highly variable, even when the coronary occlusion occurs in a similar location. On the basis of these findings, they suggested that the determination of the amount of myocardium at risk was therefore crucial in the assessment of acute intervention in myocardial infarction.
99mTc-hexakis~2-methoxy-2 -methylpropyl-isonitrile (Tc-Sestamibi) is a new radiopharmaceutical that appears useful for myocardial perfusion imaging.14-20 Like`01T1, Tc-Sestamibi is rapidly cleared from the blood pool and accumulates in normal myocardium in direct proportion to blood flow. '4 In the setting of acute coronary occlusion, a close relation exists between the distribution of microspheres and the circumferential count profile on tomographic Tc-Sestamibi images. 19 Unlike "1T1, Tc-Sestamibi has a very slow washout from the myocardium with minimal redistribution.14 Imaging can therefore be delayed for up to 6 hours and still provide information about the distribution of myocardial perfusion at the time of administration. This radiopharmaceutical should therefore be ideal in assessing the amount of myocardium at risk in acute myocardial infarction without requiring any delay in the administration of thrombolytic therapy. This pilot study was designed to assess the feasibility of using this radiopharmaceutical for this purpose and to determine its potential role in assessing the effect of treatment in myocardial infarction.
Methods

Study Population
The thrombolysis group consisted of 11 patients who were enrolled in Phase IIB of the Thrombolysis in Myocardial Infarction study (TIMI). The eligibility criteria for the study are described in detail elsewhere.21 In brief, the inclusion criteria were 1) chest pain of at least 30 minutes in duration, 2) electrocardiographic ST segment elevation of 0.1 mV or more in at least two leads, and 3) initiation of intravenous tissue-type plasminogen activator therapy within 4 hours of the onset of chest pain. There were 19 specific exclusion criteria for the TIMI trial, which were related primarily to contraindications to thrombolytic therapy. There were three additional exclusion criteria for this study: 1) evidence of previous myocardial infarction, 2) any nuclear medicine study with 99mTc within 48 hours of presentation, and 3) clinical instability preventing transport within 6 hours of Tc-Sestamibi administration to the Nuclear Cardiology Laboratory for tomographic imaging.
The conventional treatment group consisted of five patients who were admitted during the same time period with chest pain of at least 30 minutes in duration and ST elevation of 0.1 mV or more in at least two electrocardiographic leads and who were not treated with thrombolytic therapy. These patients were excluded from entry into the TIMI trial because they either had chest pain of more than 4 hours in duration (four patients) or had a contraindication to thrombolytic therapy (one patient). Two patients in the conventional treatment group had an unsuccessful attempt at acute percutaneous transluminal coronary angioplasty (PTCA) ( Table 1) . The remaining three patients did not undergo attempted revascularization within 24 hours of presentation.
Eleven patients (six in the treatment group and five in the control group) were enrolled at the Mayo Clinic. Five patients in the treatment group were enrolled at Baylor College of Medicine.
The location of the infarction was assigned (anterior, inferior, or lateral) according to the location of the electrocardiographic leads with ST elevation.
Clinical Care
All patients were admitted to the Coronary Care
Unit and received conventional therapy, including oxygen, nitrates, and morphine, as required. In the thrombolysis group, patients received 100 mg intravenous recombinant tissue-type plasminogen activator during 6 hours: 60 mg during the 1st hour, 20 mg during the 2nd hour, and 5 mg during each of the next 4 hours. These patients also received prophylactic lidocaine, intravenous heparin, and low-dose aspirin according to predetermined guidelines. In accordance with the TIMI Phase IIB protocol, patients in the thrombolysis group were randomized to (1) acute intravenous metoprolol therapy or no acute /-blocker therapy and (2) early cardiac catheterization at 18 to 48 hours with PTCA of the infarct-related artery or cardiac catheterization at 8-10 days unless necessary sooner for the management of recurrent ischemic events.
In the conventional treatment group, patients received additional therapy, including heparin, aspirin, /3-blockers, cardiac catheterization, and PTCA, according to the judgment of their staff cardiologist. Radionuclide Acquisition Tc-Sestamibi was prepared using a sterile, nonpyrogenic, lyophilized kit. After 99mTc was added, the mixture was boiled for 10 minutes. After subsequent cooling, radiochemical purity was confirmed using thin-layer chromotography. The total preparation time was approximately 30 minutes. Kits were prepared every 6 hours on a routine basis so that they were immediately available for injection. After giving informed consent, each patient received 20-30 mCi of Tc-Sestamibi intravenously before the initiation of thrombolytic therapy. Radionuclide acquisitions were performed 1-6 hours later with a commercially available rotating gamma camera (Elsinct, Haifa, Israel or Adac Laboratories, Sunnyvale, California). Thirty images (64 x 64 matrix)
were acquired for 40 seconds each, at every 60 Short-axis slices of the left ventricle were obtained every pixel (6 mm) and normalized to the peak counts in the heart for each set of images. Circumferential count profiles were generated for three representative apical, midventricular, and basal slices by identifying the peak counts in every 60 sector around the left ventricle. Each pixel in this circumferential count profile was normalized by the peak value in the profile. The Sestamibi studies ( Figure 5 ). The The present study suggests that the uptake of Tc-Sestamibi 6-14 days after infarction does indicate "functional" myocardium. The Previous assessments of therapy in acute myocardial infarction have used measurements of resting ejection fraction3-10 and thallium defect size10-12 measured after infarction or of the change in resting ejection fraction measured during and after infarction.4,9 Perfusion or function measurements obtained after infarction are clearly dependent on the amount of myocardium at risk initially as demonstrated by Feiring et al13 and by this study. The variability in the amount of myocardium at risk will therefore be a potential obstacle in the detection of any treatment benefit, except in large randomized trials where the amount of initially hypoperfused myocardium will presumably be similar in treated and control patients. In the present study, neither late resting ejection fraction nor the final amount of hypoperfused myocardium were significantly different in the thrombolysis group compared with the conventional treatment group. In this small number of patients, any treatment effect on these end points was presumably obscured by the wide variation in myocardium at risk.
The use of the change in resting ejection fraction measured during and after infarction could provide some adjustment for the amount of initially hypoperfused myocardium. Simoons et a18 and Guerci et a19 found that the change in ejection fraction showed a more significant treatment effect than the ejection fraction after infarction. However, the resting ejection fraction measured during infarction is influenced by many factors other than the amount of hypoperfused myocardium, including preload, afterload, duration of myocardial ischemia, and hyperkinesia in normal segments. These factors could contribute to the large spontaneous changes that occur in ejection fraction during the first 24 hours of acute myocardial infarction.37 Measurement of acute resting ejection fractions were not obtained in the present study. However, Feiring et al13 showed that these ejection fractions did not correlate with the amount of myocardium at risk. Thus, the end points previously used to assess acute intervention in myocardial infarction probably do not adequately adjust for the variable amount of initially hypoperfused myocardium. This could account for the failure to show significant myocardial salvage in studies or subgroups that involved relatively small numbers of patients. The change in hypoperfused region assessed by tomographic imaging with TcSestamibi appears to be a promising measurement tool, which adjusts for the variable amount of initially hypoperfused myocardium. Possibly, the final images can be obtained much earlier after therapy to assess efficacy. Further studies are needed to determine the relation between Tc-Sestamibi uptake early after myocardial infarction and myocardial blood flow and viability.
The wide range in the change in the amount of hypoperfused left ventricle could be related to many factors, including the presence and timing of acute reperfusion. Because angiography during the acute conditions was not routinely performed, we could not determine whether or not thrombolysis produced successful reperfusion, and we could not determine the timing of this event. There was no correlation between time to therapy and the change in hypoperfused myocardium in the thrombolysis group. The three patients in the thrombolysis group (patients 3, 6, and 9) with documented occlusion 48 hours after therapy had the smallest amount of change (-5, -9, and -3, respectively). None of the conventional treatment patients had spontaneous reperfusion, which might have altered the final amount of hypoperfused myocardium.
The quantitative method used in the present study has several limitations. Its validation is based on a static cardiac phantom, which does not take into account cardiac motion, areas of low but not absent flow, variable patient background, and variable myocardial shape and thickness. The count density in Tc-Sestamibi images is sufficient to permit the future use of gated tomographic imaging that would minimize motion. The close correlation (r=0.95) between pathologic and tomographic infarct size in a permanent occlusion animal model with a similar threshold technique20 would suggest that the error due to areas of low flow is minimal. The variability in background and myocardial shape and thickness in individual patients contribute to possible error. There is also a potential error due to under-sampling using this three-slice method compared with a method in which all slices are analyzed.
The percentage of hypoperfused myocardium for several of the patients who survived anterior myocardial infarctions exceeded 50%, which appears to conflict with the widely accepted notion that cardiogenic shock occurs with infarction of more than 40% of the left ventricle. Of note, however, this figure is based on the study of Page et al,38 which was an autopsy series that concluded that patients who died in cardiogenic shock had more than 40% of the left ventricle involved; no survivors of myocardial infarction were included in their study. Clinical experience with echocardiography, radionuclide angiography, and contrast ventriculography suggests that many survivors of myocardial infarction with large left ventricular aneurysms have considerably more than 50% of the ventricle infarcted. The data of Feiring et al13 tend to confirm this impression; five of their 13 patients with anterior myocardial infarctions had involvement of more than 40% of the left ventricle.
The Tc-Sestamibi methodology used here offers promise as an adjunct in clinical decision making for individual patients with acute myocardial infarc-tion. However, there are several practical difficulties that must be overcome to permit its widespread clinical application. First, the preparation kit currently used requires 30 minutes for preparation. It does not contain any bacteriostatic agent and must therefore be administered within 6 hours. To permit the rapid administration of Tc-Sestamibi without delaying thrombolytic therapy, kits must be prepared routinely four times daily. Such frequent preparation is clearly impractical. The addition of a suitable bacteriostatic agent should help to reduce the frequency of preparation. Second, the acquisition of tomographic images requires equipment that is not currently available in many community hospitals and includes potential hazards involved in the transportation of critically ill patients. Planar imaging could provide a reasonable alternative to tomographic imaging but would do so at the cost of some loss of localization and perhaps quantitative accuracy. Analysis of the planar studies performed as part of this multicenter trial is currently underway; these studies will be the subject of a separate report. Although these practical issues could limit the widespread clinical utilization of tomographic imaging with Tc-Sestamibi in acute myocardial infarction, we believe that these data show its feasibility and promise as a measurement tool for assessing acute intervention strategies in any future clinical trials.
